Format

Send to

Choose Destination
See comment in PubMed Commons below
Internist (Berl). 2008 Aug;49(8):947-8, 950-3. doi: 10.1007/s00108-008-2058-3.

[Anti-TNF biologics in the treatment of chronic inflammatory bowel disease].

[Article in German]

Author information

  • 1Klinik f├╝r Allgemeine Innere Medizin, Universit├Ątsklinikum Schleswig-Holstein, Campus Kiel, Schittenhelm Strasse 12, 24105, Kiel, Germany.

Abstract

The utility of infliximab as a therapy for complicated inflammatory bowel disease (Crohn's disease, ulcerative colitis) has been established through large prospective trials in the last decade. With approval of adalimumab physicians and patients now have the choice between two different anti-TNF agents. In addition to control of inflammation, the avoidance of chronic exposure to glucocorticoids has become a primary reason to use anti-TNF therapy. Early use of anti-TNF therapy in the course of disease is a potential new indication. The increasingly critical appreciation of side effects promotes mono-therapy with anti-TNF agents.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk